Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Whole Cell Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103642849A details a high-yield Geotrichum candidum reduction method for chiral intermediates, offering significant cost and supply chain advantages.
Patent CN102382780B reveals a novel Microbacterium oxydans strain for high-purity chiral alcohol production, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN112063531B reveals a novel Geotrichum candidum strain for Ticagrelor intermediate synthesis, offering high stereoselectivity and reduced manufacturing costs.
Novel biocatalytic route for (R)-1-(4-bromophenyl)-2,2,2-trifluoroethanol using Cyberlindnera saturnus. High ee, mild conditions, scalable pharma intermediate production.
Patent CN113462728A details a novel whole-cell biocatalytic route for high-purity chiral intermediates, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN112048538B reveals a high-yield biocatalytic route for Aprepitant intermediates using Cyberlindnera saturns, offering superior purity and cost efficiency.
Patent CN102382780A reveals a novel Microbacterium oxydans strain for high-purity chiral alcohol production, offering significant cost reduction and supply chain stability for global API manufacturers.
Patent CN112458143B reveals a novel whole-cell catalytic route for Ezetimibe intermediates. Discover how this green biocatalysis technology reduces costs and ensures supply chain stability.
Patent CN102154384A reveals efficient recombinant E. coli method yielding >26g/L with >99% ee, offering significant cost and supply chain advantages.
Novel Aeromonas caviae B18 strain enables high-purity chiral intermediate production with reduced costs and simplified downstream processing for pharma.
Patent CN105177069A details high-yield biocatalysis for chiral intermediates. Offers sustainable manufacturing and supply chain reliability for global pharmaceutical partners.
Patent CN105087668A reveals high-yield biocatalytic route for chiral intermediates. Achieve cost reduction and supply reliability with green manufacturing processes.